Efficacy and tolerability of bromelain in patients with chronic rhinosinusitis--a pilot study

B-ENT. 2013;9(3):217-25.


Objectives: To evaluate the efficacy, tolerability, and impact on quality of life (QoL) of bromelain tablets (500 FIP) in patients with chronic rhinosinusitis (CRS).

Methods: In this prospective, open-label observational pilot study, 12 patients suffering from CRS with (CRS+NP) or without (CRS-NP) nasal polyps who had undergone prior sinus surgery were treated with bromelain tablets (500 FIP) for three months. Efficacy was evaluated using symptom scores (Total Symptom Scores: TSS); a Total Rhinoscopy Score (TRS) was also determined. QoL was assessed by using the German, adapted version of the Sinonasal Outcome Test 20 (SNOT-20 GAV).

Results: Treatment with bromelain tablets (500 FIP) improved TSS, TRS and SNOT-20 GAV on average. This treatment was found to be more effective, however, for CRS-NP than for CRS+NP. The average intake was six tablets, equivalent to a daily dosage of 3000 FIP. No adverse events were observed.

Conclusion: Preliminary results indicate good tolerability, symptom control, and improvement in QoL for the treatment of CRS using bromelain tablets (500 FIP).

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Bromelains / therapeutic use*
  • Chronic Disease
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nasal Polyps / complications
  • Pilot Projects
  • Prospective Studies
  • Quality of Life
  • Rhinitis / drug therapy*
  • Sinusitis / drug therapy*
  • Treatment Outcome


  • Anti-Inflammatory Agents, Non-Steroidal
  • Bromelains